Fmoc-β-[2-pyridyl]-D-Ala

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-β-[2-pyridyl]-D-Ala
• 英文别名: Fmoc-D-Pal；Fmoc-D-3-(2-pyridyl)Ala-OH；(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(pyridin-2-yl)propanoic acid；(2R)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-pyridin-2-ylpropanoic acid
• 化学式: C₂₃H₂₀N₂O₄
• mdl: MFCD00672565
• 分子量: 388.423
• InChiKey: DXIVJCDZOMUITR-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.173
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Fmoc-β-[2-pyridyl]-D-Ala 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 2.5h， 生成 (R)-3-(3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-carboxyethyl)pyridin-1-ium-1-yl)propane-1-sulfonate
  参考文献：
  名称：

  [EN] ZWITTERIONIC COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS ZWITTERIONIQUES ET LEURS UTILISATIONS

  摘要：

  The present application relates to zwitterion compounds of Formula I, to processes of their preparations, to conjugates thereof, to compositions comprising them and to their use in diagnostics and/or therapy. wherein Q is selected from Q1, Q2, Q3, Q4 and Q5:

  公开号：

  WO2023235985A1

文献信息

• Design and Synthesis of Potent Hexapeptide and Heptapeptide Gonadotropin-Releasing Hormone Antagonists by Truncation of a Decapeptide Analogue Sequence
  作者：Dror Yahalom、Shai Rahimipour、Yitzhak Koch、Nurit Ben-Aroya、Mati Fridkin

  DOI：10.1021/jm990433g

  日期：2000.7.1

  truncation strategy was successful for generation of reduced-size hexapeptide and heptapeptide antagonists possessing potent antagonistic capacity. The same methodology was not suitable for the generation of reduced-size agonists, suggesting different conformational characteristics for GnRH agonists and antagonists. A heptapeptide antagonist designed by this method was shown to inhibit serum levels of luteinizing

  开发了一种设计减小十肽促性腺激素释放激素（GnRH）类似物尺寸的新策略。与以前尝试从任一肽的末端删除残基的尝试相反，我们的方法基于已知的GnRH类似物的C端和N端对受体识别的重要性，而分子的中心部分被短的取代垫片。当前的截断策略成功地产生了具有有效拮抗能力的尺寸减小的六肽和七肽拮抗剂。相同的方法不适用于减小尺寸的激动剂的产生，这提示GnRH激动剂和拮抗剂的构象特征不同。通过这种方法设计的七肽拮抗剂显示在体内可抑制去势大鼠血清黄体生成素的水平。结构活性研究表明，GnRH受体识别的结构偏好与十肽拮抗剂报道的相似。我们的研究产生了一种七肽GnRH拮抗剂（Ac-D-Nal2-D-Cpa-D-Pal-Gly-Arg-Pro-D-Ala-NH2），与之相比，该受体具有高受体结合亲和力（IC50 = 7 nM） GnRH本身的值（IC50 = 2 nM）。我们合成的六肽拮抗剂的最高亲和力较低（IC50 =
• Synthesis and structure–activity relationship studies of IgG-binding peptides focused on the C-terminal histidine residue
  作者：Kyohei Muguruma、Mayu Ito、Akane Fukuda、Satoshi Kishimoto、Akihiro Taguchi、Kentaro Takayama、Atsuhiko Taniguchi、Yuji Ito、Yoshio Hayashi

  DOI：10.1039/c9md00294d

  日期：——

  Currently, IgG-binding peptides are widely utilized as a research tool, as molecules that guide substrates to the Fc site for site-selective antibody modification, leading to preparation of a homogeneous antibody–drug conjugate. In this study, a structure–activity relationship study of an IgG-binding peptide, 15-IgBP, that is focused on its C-terminal His residue was performed in an attempt to create

  目前，IgG结合肽已被广泛用作研究工具，可将底物引导至Fc位点的分子以进行位点选择性抗体修饰，从而制备出均一的抗体-药物偶联物。在这项研究中，进行了一项针对IgG结合肽15-IgBP的结构-活性关系研究，该研究的重点是其C末端His残基，以试图创建更有效的肽。被2-吡啶基丙氨酸（2-Pya）取代His17的肽显示出良好的结合亲和力（15-His17（2-Pya），K d = 75.7 nM）。结合先前的结果，我们获得了15-Lys8Leu / His17（2-Pya）-OH，它们显示出强大的结合亲和力（K d = 2.48 nM），并且避免了有关p的三个合成问题C末端的-羟基苄基酰胺化，与His7位置偶联和2-Pya的外消旋化有关的困难。
• Chemically Accessible Hsp90 Inhibitor That Does Not Induce a Heat Shock Response
  作者：Yen Chin Koay、Jeanette R. McConnell、Yao Wang、Seong Jong Kim、Laura K. Buckton、Flora Mansour、Shelli R. McAlpine

  DOI：10.1021/ml500114p

  日期：2014.7.10

  Recent cancer therapies have focused on targeting biology networks through a single regulatory protein. Heat shock protein 90 (hsp90) is an ideal oncogenic target as it regulates over 400 client proteins and cochaperones. However, clinical inhibitors of hsp90 have had limited success; the primary reason being that they induce a heat shock response. We describe the synthesis and biological evaluation of a new hsp90 inhibitor, SM253. The previous generation on which SM253 is based (SM145) has poor overall synthetic yields, low solubility, and micromolar cytotoxicity. By comparison SM253 has relatively high overall yields, good aqueous solubility, and is more cytotoxic than its parent compound. Verification that hsp90 is SM253's target was accomplished using pull-down and protein folding assays. SM253 is superior to both SM145 and the clinical candidate 17-AAG as it decreases proteins related to the heat shock response by 2-fold, versus a 2-4-fold increase observed when cells are treated with 17-AAG.
• Methods for synthesis of encoded libraries
  申请人：Morgan Barry

  公开号：US20070042401A1

  公开（公告）日：2007-02-22

  The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag.
• Methods for identifying compounds of interest using encoded libraries
  申请人：Morgan Barry

  公开号：US20070224607A1

  公开（公告）日：2007-09-27

  The present invention provides a method for identifying a compound of interest by screening libraries of molecules which include an encoding oligonucleotide tag.